{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:53:28Z","timestamp":1775915608675,"version":"3.50.1"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T00:00:00Z","timestamp":1440979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0135949","type":"journal-article","created":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T17:46:49Z","timestamp":1441043209000},"page":"e0135949","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Behavioural Assessment of the A2a\/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs"],"prefix":"10.1371","volume":"10","author":[{"given":"Anne","family":"Michel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"De Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,8,31]]},"reference":[{"issue":"16","key":"ref1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"BS Connolly","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pneurobio.2008.05.003","article-title":"Progress in Parkinson&apos;s disease-Where do we stand?","volume":"85","author":"A Toulouse","year":"2008","journal-title":"Prog Neurobiol"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","article-title":"Levodopa-induced dyskinesia: review, observations, and speculations","volume":"40","author":"JG Nutt","year":"1990","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fneur.2014.00049","article-title":"Maladaptive Plasticity in Levodopa-Induced Dyskinesias and Tardive Dyskinesias: Old and New Insights on the Effects of Dopamine Receptor Pharmacology","volume":"5","author":"A Cerasa","year":"2014","journal-title":"Front Neurol"},{"issue":"Suppl 1","key":"ref5","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(11)70038-4","article-title":"Striatal plasticity in Parkinson&apos;s disease and L-dopa induced dyskinesia","volume":"18","author":"MM Iravani","year":"2012","journal-title":"ParkinsonismRelat Disord"},{"issue":"5\u20136","key":"ref6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00008877-200609000-00005","article-title":"How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson&apos;s disease?","volume":"17","author":"AR Carta","year":"2006","journal-title":"Behav Pharmacol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2008.09.013","article-title":"Priming for l-dopa-induced dyskinesia in Parkinson&apos;s disease: a feature inherent to the treatment or the disease?","volume":"87","author":"A Nadjar","year":"2009","journal-title":"Prog Neurobiol"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00702-011-0703-9","article-title":"Continuous drug delivery in early- and late-stage Parkinson&apos;s disease as a strategy for avoiding dyskinesia induction and expression","volume":"118","author":"P Jenner","year":"2011","journal-title":"JNeural Transm"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00019052-200008000-00011","article-title":"Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson&apos;s disease","volume":"13","author":"JJ Ferreira","year":"2000","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.0000000000000068","article-title":"Amantadine&apos;s role in the treatment of levodopa-induced dyskinesia","volume":"82","author":"RL Rodnitzky","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0091270009336735","article-title":"Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson&apos;s disease","volume":"49","author":"C Addy","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","article-title":"Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial","volume":"16","author":"HH Fernandez","year":"2010","journal-title":"ParkinsonismRelat Disord"},{"issue":"1","key":"ref13","first-page":"111","article-title":"Istradefylline for the treatment of Parkinson&apos;s disease","volume":"13","author":"A Park","year":"2012","journal-title":"ExpertOpinPharmacother"},{"key":"ref14","first-page":"163","article-title":"A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats","volume":"98","author":"N Jones","year":"2013","journal-title":"Brain ResBull"},{"issue":"1","key":"ref15","first-page":"285","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson&apos;s disease","volume":"184","author":"F Bibbiani","year":"2003","journal-title":"ExpNeurol"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/syn.20295","article-title":"Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors","volume":"60","author":"M Morissette","year":"2006","journal-title":"Synapse"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"PJ Blanchet","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"ref18","first-page":"S742","author":"A Michel","year":"2008"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"e114086","DOI":"10.1371\/journal.pone.0114086","article-title":"Unprecedented Therapeutic Potential with a Combination of A2A\/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson&apos;s Disease","volume":"9","author":"A Michel","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","article-title":"Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system","volume":"24","author":"U Ungerstedt","year":"1970","journal-title":"Brain Res"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuropharm.2005.12.004","article-title":"Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat","volume":"50","author":"JL Taylor","year":"2006","journal-title":"Neuropharmacology"},{"issue":"2\u20133","key":"ref22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"RK Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"issue":"6\u20137","key":"ref23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/BF01291878","article-title":"Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior","volume":"104","author":"MJ Heeringa","year":"1997","journal-title":"J Neural Transm"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s007020070083","article-title":"The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats","volume":"107","author":"G Prat","year":"2000","journal-title":"J Neural Transm"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1474-4422(14)70148-6","article-title":"Tozadenant (SYN115) in patients with Parkinson&apos;s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial","volume":"13","author":"RA Hauser","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref26","unstructured":"PBR SW. Radiprodil Trial Fails To Show Reductions In Daily Pain Scores: Forest Labs, Gedeon Richter. In: News CT, editor. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.pharmaceutical-business-review.com\/news\/radiprodil_trial_fails_to_show_reductions_in_daily_pain_scores_forest_labs_gedeon_richter_1006292010\" xlink:type=\"simple\">http:\/\/clinicaltrials.pharmaceutical-business-review.com\/news\/radiprodil_trial_fails_to_show_reductions_in_daily_pain_scores_forest_labs_gedeon_richter_1006292010<\/ext-link>."},{"key":"ref27","article-title":"The Rat Brain in Stereotaxic Coordinates","author":"G Paxinos"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.expneurol.2005.06.006","article-title":"Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson&apos;s disease?","volume":"197","author":"EL Lane","year":"2006","journal-title":"Exp Neurol"},{"issue":"2","key":"ref29","first-page":"337","article-title":"Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?","volume":"170","author":"S Konitsiotis","year":"2006","journal-title":"BehavBrain Res"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.expneurol.2004.01.018","article-title":"Antiparkinsonian activity of Ro 25\u20136981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson&apos;s disease","volume":"187","author":"PA Loschmann","year":"2004","journal-title":"Exp Neurol"},{"issue":"22","key":"ref31","first-page":"8104","article-title":"In vivo characterization of a dual adenosine A2A\/A1 receptor antagonist in animal models of Parkinson&apos;s disease","volume":"53","author":"BC Shook","year":"2010","journal-title":"JMedChem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0135949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T09:43:10Z","timestamp":1748598190000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0135949"}},"subtitle":[],"editor":[{"given":"Joohyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,31]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0135949","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,31]]}}}